CA
NZ
UK
AU
IND
US
Humana (NYSE:HUM) shares rose in pre-market trading, continuing a run that has pushed the stock above its 50-day moving average and toward multi-month highs. Humana is a Louisville, Kentucky-based health and well-being company offeringMedicareAdvantage, Medicaid, TRICARE, and commercial insurance plans, alongside integrated healthcare services …
Aethlon Medical, Inc. (NASDAQ: AEMD) shares settled up 14% at $2.47 after the company's fiscal first-quarter loss narrowed 12% to $1.55 million, mostly due to lower operating spend, with cash of $4.93 million.
ENvue Medical (NASDAQ: FEED) shares settled down 5% at $0.35 ahead of a 1-for-12Reverse Stock Splitset for September 1, 2026, intended to cut the share count to about 923,718 and help the company maintain its Nasdaq listing.
RedHill Biopharma Ltd. (NASDAQ: RDHL) shares settled up about 58% near $1.05 on Monday, August 31, 2026, versus Friday's $0.66 close, after trading as high as $1.60 on heavyVolumefollowing news of a cash asset sale.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) shares settled up 18% at $6.09 after the company posted interim Phase 2/3 data for QRX003 in Netherton syndrome, a rare genetic skin disease with few effective treatment options.
BioVie Inc. (NASDAQ: BIVI) shares settled up about 10% to 11%, near $2.38 to $2.40, versus Friday's $2.16, after the company said the last on-treatment visit is complete in ADDRESS-LC, a Phase 2 study of bezisterim for neurological Long COVID symptoms including brain fog …
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares settled down about 6%, near $2.05, versus Friday's $2.18, after the company published preclinical data in theJournalCancers on TTX-MC138 in a mouse model of breast-cancer bone metastasis.
BioAtla, Inc. (NASDAQ: BCAB) shares settled down 45% at $1.73 after Nasdaq's Listing Council upheld a delisting decision, the last internal appeal stop after the company had already failed the minimum bid-price and stockholders' equity tests.
BioLineRx Ltd. (NASDAQ: BLRX) shares settled up about 7% near $2.78 to $2.80 on Monday, versus Friday's $2.60, on a pipeline-and-runway update.
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) shares settled up about 16%, near $1.78, versus Friday's $1.54, after trading as high as the $2.20s on heavyVolumefollowing news of a constructive FDA Type D meeting held July 28 on the Phase 3 plan for CAD-1005.
Please wait processing your request...